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T he reporting of adverse drug events (ADEs) by health professionals, including pharmacists, is an important component of drug postmarketing surveillance. Pharmacists are encouraged to submit reports of serious ADEs to the Food and Drug Administration (FDA) through MedWatch.
1,2 A serious adverse event is defined as any event that is fatal, is life threatening, is permanently/substantially disabling, requires or prolongs hospitalization, causes a congenital anomaly, or requires intervention to prevent permanent impairment or damage. 3 ADE reporting is a professional obligation for pharmacists. 4 The benefits of ADE reporting have been documented elsewhere in the literature. [5] [6] [7] [8] In brief, data gathered from ADE reports alert FDA about new hazards and may reveal unusual or rare drug risks that were not discovered through premarketing trials. 1, 5 Central analysis of ADE reports helps in identifying trends of hazards 5 and facilitates learning and the prevention of future drug-related injuries. Reported ADEs also inform corrective action (e.g., labeling changes, withdrawal or restricted use of drugs) designed to improve the safety of medication-use processes. [5] [6] [7] [8] Notwithstanding the many advantages of ADE reporting, underreporting among health professionals is a major problem, 9 ,10 occurring at a rate of 50-96% annually in the United States.
11 Less than 1% of serious ADEs are reported by health professionals to FDA. 12 Many factors affect ADE reporting among pharmacists, such as attitudes, high workloads, lack of time, lack of report forms, lack of economic incentive to report, fear of appearing ridiculous, indifference, age, forgetfulness. [13] [14] [15] [16] [17] [18] [19] In addition, inadequate or limited knowledge concerning ADE reporting also plays a role. [20] [21] [22] [23] Pharmacists cannot adequately participate in ADE reporting without sufficient knowledge about ADE reporting (how, what, and why). Health professionals have been reported to have inadequate knowledge concerning ADE reporting. 14, 19, 24 However, little is known about U.S. pharmacists' knowledge of ADE reporting.
Objectives
The study objectives were to (1) assess Texas pharmacists' knowledge of ADE reporting to FDA and (2) identify demographic, professional, or setting characteristics that are associated with higher or lower knowledge levels by pharmacists. The null hypotheses for the study were (1) Texas pharmacists have inadequate knowledge of reporting ADEs to FDA and (2) pharmacists' demographic, practice, and professional characteristics are not associated with ADE reporting knowledge.
Methods
The study protocol was approved by the University of Texas at Austin Institutional Review Board. Informed consent was obtained from all participants and respondents. Anonymity of all respondents was maintained. Data were collected through a mailed survey instrument (Appendix 1 in the electronic version of this article, available online at www.japha.org). Instrument design was informed by a literature review of ADE reporting, focus group interviews, and piloting. 25 The current study was part of a broader study that investigated the predictors of Texas pharmacists' intention to report serious ADEs to FDA. 25 As part of the larger study, this study was based on a knowledge test consisting of eight true/false items that assessed respondents' knowledge concerning ADE reporting and an additional (knowledge) item that asked respondents whether they considered themselves to possess adequate knowledge of ADE reporting (true/false). The following two dichotomous questions (yes/no) that measured pharmacists' past reporting also were used in the current work: (1) Have you ever reported any ADEs to FDA through MedWatch? (2) Have you reported any ADEs to FDA through MedWatch in the previous 12 months? The following demographic and practice characteristics were collected: gender, ethnic/racial background (black, American Indian, Asian American, white, Mexican American, or other), pharmacy practice setting (community independent, community chain, hospital independent, hospital chain, or other), current job title (pharmacy owner or partner, pharmacy manager or supervisor, clinical pharmacist, staff pharmacist, relief pharmacist, or other), area/ setting of primary place of employment (urban, suburban, or PHARMACiSTS' KnOWlEDGE OF ADE REPORTinG ReseaRch rural), age (year of birth), years of experience, hours worked, and number of prescriptions/medication orders dispensed per day. In addition, all respondents were provided an opportunity to make comments about ADE reporting at the end of the survey. Some respondent pharmacists provided suggestions for improving ADE reporting.
At a Glance
The survey was pilot tested on a convenience sample of 13 hospital and community pharmacists in Austin, TX. The respondents were asked to complete the questionnaire, then give comments and feedback on the relevance and clarity of items. After the pilot test, minor modifications were made to improve the clarity of several items and the order of questions was changed. study sample and data collection An a priori power estimation was conducted using G*Power version 3.0.10 26 to determine the sample size needed to meet the goals of the study. The G*Power software determined that the total sample size for the study should be 56. The sample size was adjusted in consideration of potential low response rates. The adjusted sample size was calculated as the ratio of the number of responses needed and the expected response rate (0.36, calculated from response rates obtained in previous studies).
The adjusted sample size was calculated to be 56/0.36, n = 156. Thus, at least 200 questionnaires were to be distributed to achieve 56 responses. This adjusted sample size was meant to accommodate for anticipated missing data and unreturned questionnaires. Because we had resources for a larger sample and to counter for an unexpected low response rate, we increased the sample size to 1,500.
A random sample of 1,500 active pharmacists was drawn from a Texas State Board of Pharmacy list of licensed Texas pharmacists practicing in the hospital and community settings (n = 12,904). Only registered and currently active pharmacists practicing in the state of Texas and working in community (independent, chain, clinic, and other) and hospital pharmacies were included.
A survey packet, including a cover letter explaining the purpose of the project and a self-addressed postage-paid questionnaire, was mailed to the study sample. Respondents were asked to return the questionnaire within 2 weeks. Three weeks after the initial mailing, a reminder package was sent to pharmacists. The initial surveys were mailed in May 2009. Questionnaires were collected over an 8-week period (June and July 2009).
Data analysis
Descriptive statistics were computed for all study variables. Each participant's knowledge level was computed by summing all correct items, then dividing by the total number of items. This score was later converted to a percentage. Correlation analyses were used to examine whether pharmacists' age, years of experience, and hours worked were related to their knowledge level. An independent-group t test was used to examine the differences in knowledge scores between male and female pharmacists. Analysis of variance (ANOVA) was used to determine whether pharmacists' knowledge levels differed by gender, ethnic and racial background, job title, type of practice setting, and area/setting of primary place of employment. Tukey's post hoc tests were performed to determine significant and nonsignificant mean differences for all significant ANOVAs. Data analyses were conducted using SPSS version 14.0 (SPSS, Chicago).
Results
A total of 69 letters were returned undeliverable. Therefore, 1,431 letters were considered delivered. A total of 399 surveys were received via mail by the deadline (July 31, 2009), for a response rate of 27.9%. Of the 399 returned questionnaires, a total of 377 responses were complete and usable, for an adjusted response rate of 26.4%.
Most of the respondent pharmacists were white/nonHispanic white (70.2%) and men (52.9%) with a mean (±SD) age of 51.5 ± 12.7 years. Respondents worked 38.4 ± 10.6 hours per week and had 25.0 ± 13.0 years of practice experience. Pharmacists dispensed 174.7 ± 119.7 prescriptions/ medication orders per day. Many pharmacists practiced in community chain settings (42.2%) and worked in urban areas (46.7%). Many respondents were staff pharmacists (42.4%) and spent 30.8 ± 14.8 hours per week dispensing medications/interacting with patients. A total of 256 pharmacists (67.9%) indicated that they had never reported ADEs during their career. Only 25 pharmacists (6.6%) had reported any ADEs in the previous 12 months.
Knowledge levels
The average knowledge level across all eight items was 75.3%, or six correct items (range 12.5% [one correct] to 100% [eight correct]). Pharmacists scored low on some knowledge items, and the percent of respondents who chose the correct answer for the eight items ranged from 56.7% to 96.0% (Figure 1 ). Regarding the item with the lowest average number of correct responses, 43.3% of pharmacists thought that all ADEs, regardless of severity, should be reported to FDA. Further, 35.1% did not know that they could report serious ADEs to FDA even if they did not have all the details (complete patient history and demographic data) (Figure 1 ). These percentages were consistent with respondents' perceptions of the adequacy of their knowledge. A majority of respondents (n = 247 [65.7%]) indicated that they had inadequate knowledge concerning ADE reporting (e.g., what to report, how to report).
Relation between knowledge level and pharmacists' demographic and practice characteristics A statistically significant negative correlation was observed between knowledge levels and age of pharmacists (r = -0.106, P = 0.042, n = 365) and years of experience practicing pharmacy (r = -0.134, P = 0.010, n = 374). Knowledge level and number of hours worked by pharmacists per week were significantly and positively correlated (r = 0.130, P = 0.012, n = 374). However, no statistically significant correlation was A significant difference was observed in pharmacists' mean knowledge of ADE reporting and type of practice setting (F = 7.49; df = 4, 371; P < 0.001). The knowledge score for hospital chain pharmacists (83.4 ± 17.7) was significantly higher than that for community independent (68.1 ± 17.1) and community chain (74.2 ± 17.7) pharmacists (α < 0.05). In addition, the "other" group (80.4 ± 17.7) had a significantly higher mean knowledge level than the community independent group (69.1 ± 17.1; P < 0.05). No other group mean differences were statistically significant ( Table 1) .
The study results showed a statistically significant difference in mean knowledge of ADE reporting by current job title (F = 4.75; df = 5, 370; P < 0.001). Knowledge scores for the clinical pharmacist group (81.8 ± 15.2) were significantly higher than those for the pharmacy owner/partner (69.6 ± 18.2) and relief pharmacist (67.2 ± 17.2) groups (α < 0.05). Also, the "other" group (90.0 ± 12.9) had significantly higher knowledge scores than the pharmacy owner/partner and relief pharmacist groups. The remaining between-group mean differences were not statistically significant (Table 1) .
A statistically significant difference in mean knowledge was seen for ADE reporting among pharmacists practicing in different areas/setting of primary place of employment (F = 4.54; df = 2, 371; P = 0.011). Knowledge scores for the urban group (78.3 ± 16.2) were significantly higher than those for the suburban (73.1 ± 18.9) and rural (72.5 ± 17.7) groups (α < 0.05). The other group mean differences were not statistically significant (Table 1) .
Knowledge level and aDe reporting A statistically significant difference in knowledge scores was observed between pharmacists who had ever reported (82.2 ± 16.1, n = 120) and those who had never reported (72.02 ± 17.3, n = 256) ADEs to FDA in the past (t = -5.429, df = 374, P < 0.001). In addition, pharmacists who had reported ADEs in the previous 12 months (85.9 ± 13.9, n = 24) had a significantly higher knowledge level than those who had not reported ADEs in the previous 12 months (74.5 ± 17.6, n = 352) (t = -3.113, df = 374, P = 0.002). 7. Adverse experiences with cosmetics and special nutritional products (e.g., dietary supplements, infant formulas) may be reported to FDA.
6. Pharmacists can report ADEs to FDA anonymously.
5. FDA does not disclose the ADE reporter's identity in response to a request from the public.
4. All serious ADEs are known before a drug is marketed.
3. Pharmacists should report serious ADEs even if they do not have all the details (e.g., complete patient history, demographic data).
2. Pharmacists should report serious ADEs even if they are uncertain that the product caused the event.
1. All ADEs, irrespective of severity, should be reported to FDA. PHARMACiSTS' KnOWlEDGE OF ADE REPORTinG ReseaRch suggestions for improving aDe reporting Survey comments by pharmacists pertaining to knowledge of ADE reporting included the following: "I would like a refresher on ADE reporting," "There should be continuing education on ADE and reporting," "I would like to know more details on this subject," and "All employers should include ADE reporting in their training modules for employeesmandatory!"
Discussion
As hypothesized, findings from this study showed that a majority of respondents (65.7%) perceived themselves to have inadequate knowledge concerning ADE reporting, which was corroborated by anecdotal comments made by some respondents on their questionnaires and the low scores on some knowledge items. For example, 43.3% of the pharmacists thought that all ADEs, regardless of severity, should be reported to FDA, whereas MedWatch stipulates that only serious ADEs should be reported. Taken together, these findings suggest a substantial lack of knowledge of ADE reporting among pharmacists and corroborate previous research suggesting that medical professionals [27] [28] [29] [30] and pharmacists 14, 17, 24, 31 have deficient ADE/adverse drug reaction (ADR) reporting knowledge. For example, Green et al.
14 reported that U.K. hospital pharmacists had inadequate knowledge on the purpose and usefulness of the information collected by the Yellow Card spontaneous ADR reporting system. Limited knowledge of ADE reporting may reduce the number of reports submitted by pharmacists. Lack of these data delays the identification of drug hazards and reduces the likelihood of generating signals about unexpected and uncommon ADEs, with substantial ensuing public health repercussions (unnecessary and avoidable patient harm).
Contrary to our hypothesis, in this study, age, type of practice setting, current job title, and area/setting of primary place of employment were found to be associated with knowledge on ADE reporting. The lack of knowledge was found to be more acute among older pharmacists, those working in community pharmacies (chain and independent), pharmacy owners/partners, relief pharmacists, and those working in rural and suburban settings. Why these factors were associated with knowledge is unclear. Few studies have investigated the relationship between knowledge and personal and professional characteristics. The relationship between type of practice setting and knowledge of pharmacists found in the current work is consistent with other studies. Cox et al. 32 reported that hospital pharmacists were better informed about pharmacovigilance than community pharmacists. This may be explained by the fact that hospital pharmacists have more access to pertinent information (e.g., lab results), 33 are exposed to more serious ADEs (because the most serious ADEs occur in hospital), 34 and are more likely to receive ADR information from physicians 13 than community pharmacists. However, the following also has been reported: "Pharmacists in retail settings were more likely than hospital pharmacists to be aware of ADRs relating to therapeutic inequivalence and over-thecounter products." 13 The study results also showed a positive relationship between knowledge level and past ADE reporting behavior. Thus, higher reporting can be attained by increasing pharmacists' knowledge of ADE reporting. Previous studies found the same relationship between knowledge and reporting. 14, 17, [35] [36] [37] [38] [39] Education interventions were found to increase reporting and improve quality of reports. 36, [38] [39] [40] [41] For example, in Portugal, a cluster-randomized controlled trial involving an education intervention resulted in a 10-fold increase in the number of ADR reports. 36 An example is the Rhode Island Department of Health's physician education project conducted in 1986 and aimed at increasing physician reporting rates. The Rhode Island Department of Health provided physicians with education on the reporting system. 20 As a result of the project, the number of reports increased 17-fold, from an average of 11.6 per year (1981-85) to 209 direct reports in 1988. By improving pharmacists' knowledge levels concerning ADE reporting, education interventions can potentially increase ADE reporting rates. All relevant stakeholders (e.g., FDA, employers, managers/bosses) should prioritize and support ADE reporting education and training for pharmacists.
More should be done to enhance ADE reporting knowledge among all pharmacists and specifically older pharmacists, those working in community pharmacies (chain and independent), pharmacy owners/partners, relief pharmacists, and those working in rural and suburban settings. More and different types of training and education programs (continuing education and seminars) related to ADE reporting targeted at pharmacists are warranted. Specifically, pharmacists need more education on the types of ADEs that are to be reported, how to report, what constitutes a good report, definition of serious ADEs, the operations of MedWatch, and the benefits/value of pharmacovigilance and reporting. This is consistent with the suggestions of pharmacists surveyed in the current study regarding ways to increase ADE reporting.
Education interventions also should be targeted at student pharmacists, who have been found to have inadequate knowledge of ADE reporting. It has been reported that only 13.4% of third-year student pharmacists from nine colleges of pharmacy were aware of MedWatch. An even smaller percentage of students (4%) demonstrated understanding associated with the MedWatch program. Improvements in pharmacy education are necessary to enhance student awareness and knowledge of ADE reporting. Use of different mechanisms to teach students about ADE reporting, such as experiential rotations, work experience, and didactic courses, would be helpful.
Limitations
First, despite using a second mailing to improve the survey response rate, only 26.4% of the selected sample returned ReseaRch PHARMACiSTS' KnOWlEDGE OF ADE REPORTinG complete and usable surveys. Nonresponse bias may be a problem given the low response rate. This low response rate may limit the generalizability of the results from this study. However, no statistically significant difference occurred regarding ethnic/racial background and gender between the respondents (n = 377) and the targeted random sample (n = 1,500). Second, the number of respondents in the hospital practice setting (independent and chain) in this study was fewer than those in the community pharmacy setting (independent and chain). However, the relative proportions were similar to those in the random sample. Third, because the study was anonymous, nonresponders and responders could not be compared. Fourth, this study was cross sectional in nature and provided data on the existing situation at a particular point in time. The results could change over time. Next, we would like you to answer the following two statements in a general sense. Please circle the number that corresponds to your choice using the scales listed below. 
THANK YOU FOR YOUR PARTICIPATION!

